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The paper presents results of the analysis of illicit synthetic drugs in the form of tab-
lets distributed under the name “Ecstasy”, seized by the police in the broader area of
Novi Sad 2004. A huge number of tablets has been analyzed (n=121), of various colours 
and with impressed symbols from the total amount of 93 seizures, which totally amount-
ed to 1458 tablets. Regarding the number of seizures ecstasy (3,4-methylendioxy-N-meth-
yl-amphetamine – MDMA) is dominant among all, and according to the quantity of seized 
tablets it is amphetamine (AP), while other amphetamine-type drugs (methamphetamine 
– MA, 3,4-methylendioxiamphetamine – MDA, 3,4-methylendioxi-N-ethyl-amphetamine 
– MDEA) have been found in rather small quantities and very rarely. Tablets mostly con-
tain caffeine as an additive.
In the analytical procedure, the samples of tablets were subjected to liquid-liquid ex-
traction and afterwards analyzed on the GCD (GC-EI) Hewlett-Packard instrument. The
method is fast, reliable and reproducible for the analysis of amphetamine, metham  phe-
tamine, MDA, MDMA, MDEA, as well as various additives in the samples of seized tab-
lets. 
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INTRODUCTION
Expansion of usage of synthetic hallucinogens in the last three decades has been ob-
served worldwide, that has also been evident in our country. The drugs most frequently 248
abused by young population are amphetamine and its derivatives methamphetamine (MA), 
3,4-methylendioxy-N-methyl-amphetamine (MDMA), 3,4-methylendioxy-amphetamine 
(MDA) and 3,4-methylendioxy-N-ethyl-amphetamine (MDEA). Increased popularity of 
these drugs, especially of ecstasy or MDMA, originates from the illusion of having ex-
tremely high energy, euphoria, control of inhibition, and belief that they are “safe drugs”. 
Of course, this belief is false, since a huge number of intoxications, even fatalities, have 
been recorded. 
3,4-Methylendioxy-N-methyl-amphetamine (MDMA), the popular name “Ecstasy”, 
was developed by E. Merck Pharmaceutical Company in Germany in 1914, in an attempt 
to produce a new appetite suppressant, although it was never distributed on the market or 
gained general acceptance. In the 1970’s and early 1980’s the drug was investigated again 
as an adjunct to psychotherapy based on its reported ability to improve interpersonal com-
munications and enhance emotional awareness (1-4). Prior to its classiﬁcation as a Sched-
ule I drug in 1985. in the USA, it enjoyed some popularity in the psychiatry due to its ther-
apeutic characteristics (1, 4). Namely, it has been suggested that the use of MDMA, in a 
controlled therapeutic setting, promotes trust and conﬁdence between patients and ther-
apists (5). Such reputation of MDMA is due to the fact that is generally characterized as 
an empathy-enhancing compound (6), i.e. as an empathogen or entactogen (Greek: “en” 
= inside; “gen” = to produce, originates, gives; and Latin: “tactus” = touch; i.e. “to touch 
within oneself”) (7). During the mentioned period, recreational use of MDMA was grow-
ing (6). Evidence on the widespread abuse as a recreational drug on the college campus-
es has been reported (8, 9). 
Since then MDMA (ADAM, ecstasy, E, X, XTC, M&M, euphoria, “rave”, “hug-
drug”, disco-biscuits, white doves, love drug, “rolls” and essence) has become widely abu-
sed and extremely popular as a recreational drug at parties, raves and discos. Its users re-
port as “positive” effects, the changes in feelings and emotions, enhanced communication, 
empathy and understanding, changes in cognitive or mental associations, euphoria or ec-
stasy, and changes in perception, including hallucinations (10). Other reported effects in-
clude a great sense of pleasure, dissociation, sexual stimulation, relaxation, increased re-
sponsiveness to intimate touch, increased self-esteem, high energy and tireless individu-
als (11, 12). In addition, the belief of being a “safe drug” has been widespread among the 
addicts.
However, MDMA shares the same properties as other amphetamines, acting on both 
the heart and the central nervous system, with increased release of catecholamines (includ-
ing serotonin) and prevention of reuptake (13,14). There is tremendous overlap between 
recreational and toxic levels. In seven patients who died of MDMA toxicity, blood levels 
ranged from 110 ng/mL to 1260 ng/mL. Levels in ﬁve patients who survived serious bouts 
of toxicity were from 200 to 970 ng/mL, while the levels in ﬁve car-accident victims were 
from 50 to 340 ng/mL (15, 16). Experience in Europe shows that MDMA abuse may result 
in a diverse group of psychiatric syndromes, including toxic psychosis (panic attacks, dep-
ersonalization, depression, “ﬂashbacks” and obsessive–compulsive symptoms) (17- 20).
Numbers of fatalities have been described in the British literature, and from the data 
that has been presented, it appears that the increased toxicity seen in the U.K. is, at least 
partly, a function of how the drug is used (16, 21, 22). Almost all of the case reports from 
England involve young people who develop hyperthermia, rhabdomyolysis, renal failure, 
and disseminated intravascular coagulation (22). Common to almost all the cases is the 
fact that, after taking MDMA, the victim danced for many hours in hot, poorly ventilated 
clubs. The acute effects after taking MDMA are serotonin syndrome associated with hy-249
perthermia and mental status changes and cardiovascular instability, severe hyponatremia 
induced cerebral or/and pulmonary edema and idiosyncratic hepatotoxicity. There is also 
a direct amphetamine-like effect on the cardiovascular system and hyperthermia may be 
related to the key role serotonin plays in the hypothalamus in thermoregulation (23, 24).
In many cases, the designer drugs result in a physiological effect much like the “parent 
drug” and in some cases have additional very harmful side effects. In order to successfully 
prosecute these underground activities, it is very important to be able to reliably determine 
the exact structure of the particular designer drug. Analysis of this class of compounds is 
carried out by the method SPME/GC-MS (25), GC/MS (26, 27), high performance liquid 
chromatography (HPLC) (28), infrared spectroscopy and recently, by two variants of cap-
illary electrophoresis (CE), micellar electrokinetic capillary chromatography (MECC) and 
capillary zone electrophoresis (CZE) (29).
The aim of this research was to proﬁle samples (to determine the structure) based on 
the GCD analysis of seized tablets, which were distributed as ecstasy (MDMA) on the 
“black market”, and to show diffusion of this and other similar drugs, i.e. amphetamine de-
rivatives (MA, AP, MDA, MDEA) in the broader area of Novi Sad during 2004. Analyses 
have been carried out in the laboratory of the Institute of Forensic Medicine in Novi Sad.
EXPERIMENTAL
Materials and reagents 
Seized samples of synthetic drugs in the form of tablets have been analyzed. Samples 
of tablets of various colours and impressed symbols on their surface have been distributed 
on the “black market” under the name of “Ecstasy” and originated from the seized mate-
rial from the wide area of Novi Sad, in the period January–December 2004. 
Analysis of totally 121 tablets from 93 single seizures amounting to 1458 tablets has 
been carried out. At seizures of several tablets, a number of samples considered as repre-
sentative for that seizure was analyzed, based on the method of free selection.
All used reagents were of HPLC grade.
Preparation of samples for GCD 
Samples of tablets for analysis were prepared by liquid−liquid extraction (LLE). The 
tablets were crushed and 10 mg of the homogeneous powder were added to 1 mL de-
ionized water, to which ﬁrst 100 µl buffer pH=10 (NH4Cl/NH3) have been added. The 
solution has been mixed for 20 s, and after addition of 1 mL of ethyl acetate, for another 
minute. The sample has been then centrifuged for 5 min at 3000 rpm and the organic layer 
has been taken off and dried over anhydrous Na2SO4. After ﬁltration a sample for GCD 
was obtained. 
Analytical method 
Analyses were carried out using a HP 1800A Hewlett-Packard instrument (Palo Alto, 
CA, USA). GCD is an advanced gas chromatography (GC) system introduced by Hewlett-
Packard in 1994. It consists of a gas chromatograph, an electron ionization (EI) detection 250
system for m/z up to 550 and a data system. The EI detection generates retention time, 
abundance and the mass spectral data, so that the obtained are comparable with those 
obtained with a GC – mass spectrometry (MS) instrument. The conditions of the analysis 
were as follows: capillary column (Hewlett-Packard HP5, cross linked 5% phenylmethyl-
silicone, 30 m × 0.32 mm i.d., ﬁlm thickness 0.25 µm) with helium as the carrier gas; sam-
ple volume 1µL was injected with split ﬂow (split mode) at the injection port temperature 
of 250oC, temperature of detector 280oC. The column oven temperature was programmed 
from an initial temperature of 50oC, then at a linear increase of 20oC/min to 130oC (held 
for 1 min), then at 9oC/min to 230oC (held for 3.89 min).
Components were identiﬁed by comparing their mass spectra with those found in 
reference libraries (Wiley 275, PMW-TOX3). A list of possible compounds was generated 
using an automated library search routine with probability-based matching (PBM) algo-
rithm, and each mass spectrum was visually inspected to verify the match.
RESULTS AND DISCUSSION
Active components of illicit stimulating drugs and additives that are deliberately add-
ed to increase the mass, have been determined in tablet samples seized 2004 on the broad 
area of Novi Sad. In total, 1458 tablets have been seized in 93 seizure actions, out of which 
121 tablets have been analyzed, whereby the tablets for analysis have been chosen within 
one seizure by the method of free selection.
According to the visual characteristics, the tablets differed from each other according 
to the colour and impressed symbol (logo), however there were no different tablets within 
one seizure. The most frequent impressed symbols were ”Mitsubishi”, ”Mercedes”, ”Adi-
das”, ”Puma”, ”Nike”, a star, ”yin-yang”, ”smile”, ”?” and rarely a diamond, heart, dolphin,
bow and arrow, “Batman”, X and E. The most frequent colours were beige, pink, gray and 
green. Weight of tablets was in the range from 100 to 300 mg. Since these colours, the logo 
and the structure are identical to those that are well known from the forensic literature of 
the USA and Western Europe, it makes us believe, that Vojvodina is the secondary mar-
ket for this type of narcotics and that originated from the illegal laboratories in the USA 
and Western Europe (30). 
In the seized samples, amphetamine and methamphetamine MDA, MDMA and 
MDEA have been identiﬁed. These illegal substances are on the list of narcotics “Deci-
sion on Determination of Narcotics”, Ofﬁcial Gazette (31), and any possession of them is 
punishable. The mentioned compounds were completely separated and detected, but they 
were also detected simultaneously if they were present in the same sample.
None of the compounds usually encountered in illicit samples interfere with target 
compound (e.g., amphetamine or ecstasy). This allows the detection of additives like, for 
example, caffeine and some pharmaceutical preparations that are present in these synthetic 
mixtures (barbitone, aminophenazone, etc.). Representative proﬁle chromatograms of two 
tablet samples of both amphetamine and ecstasy from different seizures are shown in Figs. 
1 – 4 and tables 1 – 4.251
Fig. 1. Proﬁle of the tablet sample of amphetamine from the October seizure
Table 1. Retention time (tR), compound and relative content (Rel. %)
of proﬁle of the tablet from Fig. 1
tR (min) Compound  Rel. %
5.66 amphetamine 25.55
10.37 N-formylamphetamine 4.26
14.70 caffeine 52.91
15.76 aminophenazone 11.15
Fig. 2. Proﬁle of the tablet sample of amphetamine from the December seizure252
Table 2. Retention time (tR), compound and relative content (Rel. %)
of proﬁle of the tablet from Fig. 2
tR (min) Compound  Rel. %
5.59 amphetamine 6.70
10.44 barbitone 18.92
14.19 4-methylbenzaldehyde 2.45
14.74 caffeine 68.33
Fig. 3. Proﬁle of the tablet sample of ecstasy from the February seizure
Table 3. Retention time (tR), compound and relative content (Rel. %)
of proﬁle of the tablet from Fig. 3
tR (min) Compound Rel. %
6.33 methamphetamine 2.35
10.93 MDMA (Ecstasy) 90.15
14.73 caffeine 6.21253
Fig. 4. Proﬁle of the tablet sample of ecstasy from the May seizure
Table 4. Retention time (tR), compound and relative content (Rel. %)
of proﬁle of the tablet from Fig. 4
tR (min) Compound  Rel. %
10.89 MDMA (Ecstasy) 90.95
11.46
3,4-methylendioxy-N-ethyl-amphetamine 
(MDEA)
8.26
On the basis of results proﬁling (structure determination) of clandestinely manufac-
tured drugs, it is clear (Fig. 1-4) that they contain a great variety of active components 
(amphetamine, MDMA, MDEA), additives (caffeine, aminophenazone) and impurities 
(4-methylbenzaldehyde, N-formylamphetamine) derived from their manufacture, and 
consequently, do not belong to a common “batch” (the same source). Because proﬁling 
serves as a tool to relate different street drug to a common sources, to determine synthetic 
routes for synthetic drugs and to identify impurities which accumulate during the synthetic 
sequence because of the lack of quality control in clandestine laboratories, and which may 
cause public health risks because of their inherent chemical or biological inﬂuences. 
Analyses have shown, that tablets distributed under the name “Ecstasy” were not al-
ways MDMA. The most frequent seizures contained ecstasy (MDMA) tablets (70 seizures 
out of 93), where the number of seized tablets predominantly varied from 1 to 3, while 
regarding the quantity of seized amphetamine tablets was dominant (761), (Table 5). 254
Table 5. Quantity of seized tablets distributed as “Ecstasy”,
expressed in number of seized tablets per month
Amphetamine Ecstasy MA MDA MDEA Ephedrine
January 202 17
February 498 282 4
March 4
April 1 23
May 3 2
June 5 23 4
July 68
August 3
September 2 13
October 31 46 2 10
November 14 7
December 5 186 2 1
Σ 761 674 6 4 3 10
Other stimulative drugs (methamphetamine – MA, 3,4-methylendioxyamphetamine 
– MDA, 3,4-methylendioxy-N-ethyl-amphetamine – MDEA and ephedrine) have been 
found in small quantities and rarely.
Fig. 5. shows percentage of the structure of the totally seized drug quantity under the 
street name “Ecstasy” 2004. As Figs. 5. and 6. show, in the number of monthly seizures, 
the largest number of amphetamine tablets was seized in January (200) and in February 
(497), they originated from a single seizure, while in March, July and August there were 
no seizures of amphetamine at all. On the other hand, MDMA has been seized every 
month.
A comparison of calendar frequency of seizures (Fig. 6) the two most frequently con-
sumed narcotics, amphetamine and MDMA, with the quantity (and the type) of seized 
drugs (Fig. 5), shows that seizures of small quantities of MDMA were carried out in the 
period March – September, with the exception of July (6 seizures, 68 tablets), which is 
partly identical with the period when the International Music Festival EXIT was held in 
our town. The slight growth of the seizure number and seized quantity of drugs can be 
noticed in October, while a signiﬁcant seizure of MDMA (11 seizures, 186 tablets) took 
place in December. The frequency of “Ecstasy” tablets seizure per month shows that a 
number of seizures have been carried out at the beginning and at the end of the year, 
whereby larger quantity of tablets has been seized, when the weather is cold, so that young 
people meet mainly at parties, raves, and in the disco and consume tablets of this type as 
a recreational drug.
The largest part of the amphetamine quantity was with additives (only ﬁve tablets out 
of 761 were pure amphetamine, it means 0.66%) and various additives were frequently 
combined. Caffeine was always present in additives 99.34% (756 tablets) and as the only 255
Fig. 5. Distribution of “Ecstasy” tablets, in percentage
(numbers on the columns represent No. of tablets of a certain kind)
Fig. 6. Number of seizures of ecstasy (MDMA) and amphetamine in 2004256
additive it was present in 721 tablets (94.74%), in combination with N-formylamphet-
amine in 28 tablets (3.68%), in combination with barbitone and 4-methylbenzaldehide 
in 4 tablets (0.53%), and with N-formylamphetamine and aminophenazone in 3 tablets 
(0.39%).
The total quantity of seized ecstasy (674 tablets) contained additives in less cases (Fig. 
7) in comparison with amphetamine.
Fig. 7. Proportion of tablets of pure MDMA and MDMA with various types of additives
Out of 674 tablets MDMA 408 (60.53%) was without additives, with caffeine as ad-
ditive there were 243 tablets (36.05%), with caffeine and methamphetamine 13 tablets 
(1.93%), and with 3,4-methylendioxy-N-ethyl-amphetamine only 10 tablets (1.48%).
As could be expected, caffeine was the most frequent additive in the analyzed tablets. 
As an additive caffeine is added in order to increase the mass of tablet, as well as for 
the individual stimulating effect on the central nervous system. N-formylamphetamine, 
4-methylbenzaldehyde and other intermediaries due to insufﬁciently controlled produc-
tion process in clandestine laboratories, may cause undesired side effects in the form of 
toxicity and effect modiﬁcation of the very active component, by which they increase the 
health risk of the addict.
Six seized tablets of methamphetamine and 4 tablets of 3,4-methylendioxiamphet-
amine were without additives, while all three tablets of 3,4-methylendioxy-N-ethyl-am-
phetamine additionally contained 3,4-methylendioxy-N-methyl-amphetamine in a small 
quantity. 
It is interesting that in one seizure of 10 tablets ephedrine has been found in combina-
tion with other pharmaceutical preparations (paracetamol, dramamine, metorfane, chlor-
feniramine). The list of narcotics in Serbia and Montenegro does not contain ephedrine 
and in this case it can be assumed that it was to serve as a drug substitution. 
CONCLUSION
From the results of the analysis it can be concluded that the dominant street drug in 
the area of Novi Sad is ecstasy (3,4-methylendioxy-N-methyl-amphetamine – MDMA), 
which is often found pure (without additives), while the next drug is amphetamine, which 
is almost always combined with additives. Other synthetic amphetamine-type drugs (MA, 
MDA, MDEA) can be found rarely in this area.257
 The most frequent tablets seizures happen at the beginning and at the end of the year. 
Periodic frequency of seizures shows its partial connection with mass manifestations for 
young people and it also shows its permanent presence on the “black market”, as well as 
the trend of increased consumption of ecstasy (MDMA) in this area.
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АНАЛИЗА ФОРЕНЗИЧКИХ УЗОРАКА ТАБЛЕТА “ЕКСТАЗИ”
ЗАПЛЕЊЕНИХ У НОВОМ САДУ ТОКОМ 2004. ГОДИНЕ
Драгана М. Згоњанин, Ева С. Лончар u Милош М. Тасић
Представљени су резултати анализе незаконитих синтетских дрога у виду таб-
лета дистрибуираних под називом “екстази”, заплењених од стране пoлиције на
ширем подручју града Новог Сада у току 2004. године. Анализиран је велики број
узорака таблета (n=121), разних боја и утиснутих симбола, из укупно 93 заплене,
што представља 1458 таблета. По броју заплена доминантан је екстази (3,4-ме-
тилендиокси-N-метил-амфетамин – МДМА), а по количини заплењених таблета ам-
фетамин (АП), док су друге дроге амфетаминског типа (метамфетамин – МА, 3,4-
метилендиоксиамфетамин – МДА, 3,4-метилендиокси-N-етил-амфетамин – МДЕА) 
нађене у минорним количинама и веома ретко. Таблете углавном садрже као адитив 
кофеин.
У аналитичком поступку узорци таблета подвргнути су течно-течној екстракцији и 
потом анализирани на GCD (GC-EI) уређају. Метода је брза, поуздана и репродуктивна 
за анализу амфетамина, метамфетмина, МДА, МДМА, МДЕА, као и разних адитива 
у узорцима заплењених таблета.
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